Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €32.58 EUR
Change Today +2.48 / 8.24%
Volume 159.1K
As of 4:38 AM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

cellectis (ALCLS) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/29/15 - €41.77
52 Week Low
10/8/14 - €8.28
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CELLECTIS (ALCLS)

Related News

No related news articles were found.

cellectis (ALCLS) Related Businessweek News

No Related Businessweek News Found

cellectis (ALCLS) Details

Cellectis, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors for the treatment of cancers. Its lead product candidate is UCART19, an engineered T-cell product candidate for the treatment of CD19 expressing hematologic malignancies that developed in acute lymphoblastic leukemia and chronic lymphocytic leukemia. The company’s products also include UCART123 for acute myeloid leukemia indications, and UCART38 and UCARTCS1 for multiple myeloma indications. It has strategic alliances with Les Laboratoires Servier SAS to develop and commercialize product candidates targeting leukemia and solid tumors; and Pfizer Inc. to generate CAR T-cells in the field of oncology. Cellectis was founded in 1999 and is based in Paris, France.

89 Employees
Last Reported Date: 03/26/15
Founded in 1999

cellectis (ALCLS) Top Compensated Officers

Co-Founder, Chairman and Chief Executive Offi...
Total Annual Compensation: €328.4K
Co-Founder, Executive Vice President of Corpo...
Total Annual Compensation: €248.8K
Compensation as of Fiscal Year 2013.

cellectis (ALCLS) Key Developments

Cellectis S.A. Presents at French Life Science Days conference, Jun-17-2015

Cellectis S.A. Presents at French Life Science Days conference, Jun-17-2015 . Venue: W Hotel, 541 Lexington Avenue, New York, NY 10022, United States.

Cellectis S.A. Announces Unaudited Consolidated Earnings Results for the Quarter Ended March 31, 2015

Cellectis S.A. announced unaudited consolidated earnings results for the quarter ended March 31, 2015. For the year, the company announced total revenues and other income amounted to EUR 9,219,000. Operating loss was EUR 3,558,000. Net income attributable to the company was EUR 6,146,000. Diluted earnings per share were EUR 0.23. Adjusted Net Income attributable to shareholders of company was EUR 7,155,000 or EUR 0.23 per share.

Cellectis May Sell Assets

Cellectis S.A. (ENXTPA:ALCLS) is planning to sell its underperforming assets than selling the whole company, industry sources told deal Reporter, according to contacts.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALCLS:FP €32.58 EUR +2.48

ALCLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
General Electric Co $26.64 USD -0.45
Lonza Group AG SFr.123.90 CHF -0.90
Sigma-Aldrich Corp $139.33 USD -0.18
View Industry Companies

Industry Analysis


Industry Average

Valuation ALCLS Industry Range
Price/Earnings 90.0x
Price/Sales 34.0x
Price/Book 4.0x
Price/Cash Flow 117.2x
TEV/Sales 34.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLECTIS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at